Larry Robbins, founder of Glenview and Chairman of Longview adds, "Butterfly is the epitome of value-based care: better health, lower cost, and patient centric. We are proud that our Butterfly investment will help accelerate efforts to provide the medical community with tools to diagnose more clearly and enable practitioners to be more effective, more efficient and more confident."
The Pro Forma enterprise value of the merger is $1.5 billion, with the combined company expected to have an estimated $584 million in cash after closing. The business combination is expected to be completed by the end of the first quarter of 2021.
Related articles:
Next-gen ultrasound-on-chip tech advances point-of-care imaging
iPhone-based "ultrasound on a chip" wins FDA clearance
Ultrasound system-on-chip 'brings any surface to life'
